Portfolio Update

Hello, Haymakers:

The main topic of this week’s Update is IJH, which has been in and out of Haymaker focus for years, but which today warrants another in-depth look. Whether it’s a name you’ve been following with us since our first mention or one you haven’t been tracking at all, you’ll want to hear us out on its recent trajectory and where we think it’s heading.

Before getting into Mid-Caps…

… we’d like to run a briefer follow-up on a much more recent Haymaker recommendation: Quest Diagnostics. This one made its initial Portfolio appearance just a couple of months back, but there’s enough activity to warrant a quick, well, diagnostic, if you will. As we don’t have as much history to cover here, the update is accordingly brief.

Enjoy the read!

We recommended Quest Diagnostics on June 5, 2026, at $200.29. The stock is trading today at approximately $236 for a gain of roughly 18% in just over two months, plus the $0.86 quarterly dividend. Considering the S&P’s ~6% gain in that time, DGX is a respectable outperformer. The Q2 earnings report on July 23 was the catalyst, with the stock surging 11.15% on the day. Our thesis has been directionally right so far and the question is whether meaningful upside remains.

Five-Year Price Chart (prior overhead resistance displayed)

Obviously, we missed the key upside range expansion early last year, but we did catch a retracement to near the breakout point not that far above $180. It was also smack dab on the 200-day moving average. Buying relatively close to the resistance penetration spot and at the 200-day is typically a profitable tactic. Fortunately, this was no exception.